Extract

The primary objective of the study is to compare, after 8 weeks, the efficacy of SR58611A vs. placebo in patients with Major Depressive Disorder who are on concomitant treatment with escitalopram. The secondary objective of this study is to document clinical safety and tolerability of SR58611A in association with escitalopram.

Inclusion criteria

• Major Depressive Disorder

Country

• Belgium
• Estonia
• Finland
• France
• Germany
• Greece
• India
• Korea, Republic of
• Malaysia
• Morocco
• Taiwan, Province of China
• Tunisia
• Turkey

Links

• ictrp
• nct